Sept 16 Kythera Biopharmaceuticals Inc
said its experimental injectable drug succeeded in reducing
double chin of patients in late-stage studies, meeting the main
and secondary goals of two clinical trials.
The company's shares jumped 10 percent on the positive data
for its lead drug, ATX-101.
Over 1000 patients with moderate to severe submental fat
were tested in the two studies conducted in the United States
and Canada, where ATX-101 was evaluated against a placebo.
Submental fat is concentrated in the area under the chin.
If approved, the drug could fulfill an unmet medical need as
there is no proven non-surgical option to effectively reduce
submental fat, said Dr Jean Carruthers, one of the investigators
of Kythera's clinical study.
The most common adverse events were swelling, pain,
bruising, numbness and redness, but none were treatment-related,
Kythera, which focuses on making aesthetic medicines, will
disclose additional data from the two studies at the American
Society for Dermatologic Surgery meeting between Oct. 3-6.
The company has said it plans to assess future potential
treatments for ATX-101 in the body.
Germany's Bayer AG holds development and
marketing rights to ATX-101 outside the United States and
Shares of Calabasas, California-based Kythera rose to $36.98
in after-market trading. The stock closed at $33.53 on the
Nasdaq on Monday.
(Reporting by Zeba Siddiqui in Bangalore; Editing by Sriraj